Sionna to Cut 46% of Workforce After CF Study Failure

Product / TechCorporate Action
โดย Zacks Investment Research·US·Read original
Summary · why it matters

Sionna Therapeutics will cut about 46% of its workforce after its cystic fibrosis pipeline suffered a key clinical setback, sending SION shares down nearly 17% yesterday. The restructuring, which Sionna expects to cost approximately $6.4 million, is aimed at lowering operating expenses and focusing resources on its prioritized CF programs, and the company says the measures should extend its cash runway into the second half of 2029. The move follows disappointing results for SION-719, a nucleotide binding domain 1 stabilizer tested as an add-on to Vertex Pharmaceuticals' marketed CF treatment Trikafta in adults homozygous for the F508del mutation; the phase IIa PreciSION CF proof-of-concept study missed its key endpoint, failing to show a statistically significant reduction in sweat chloride levels, and Sionna decided not to continue developing the candidate as a Trikafta add-on. A post-hoc analysis that excluded three participants showed a placebo-adjusted sweat chloride reduction of 8.6 mmol/L, but the company noted this was not the prespecified primary analysis and is therefore less conclusive. Sionna is now concentrating on its proprietary dual combination of SION-451 and SION-2222, which it selected as its preferred combination after a phase I study met safety, tolerability and pharmacokinetic objectives, and it intends to advance the pair into the phase IIa AscenSION CF proof-of-concept study in the first quarter of 2027. Year to date, SION's stock has plunged 83.3% against the industry's 7.8% growth.

Impact on stocks 4

Biotech & Genomic Medicine▼ · 3 stocks
Health Care▲ · 1 stocks

Theme Impact 1

Related news

3

Ascendis Pharma Regains TransCon Metabolic Rights After Novo Nordisk Split

Ascendis Pharma has regained exclusive rights to TransCon technology-based products in metabolic and cardiovascular diseases after ending its collaboration with Novo Nordisk. The company plans to advance its own programs in obesity and type 2 diabetes using its TransCon platform, with management highlighting once-monthly TransCon Semaglutide as a planned program within its expanded metabolic disease pipeline. Control of once-monthly TransCon Semaglutide and other metabolic projects shifts Ascendis from a partner model with Novo Nordisk to running these programs itself, concentrating both the potential upside and the development and commercialization costs inside one balance sheet. The regained rights and the once-monthly TransCon Semaglutide plans are only one part of the Ascendis story, and the company's existing rare endocrine portfolio still centers on YORVIPATH, SKYTROFA, and TransCon CNP or YUVIWEL. Key proof points now sit in the clinic and on the cash line, including formal trial initiation for once-monthly TransCon Semaglutide in obesity and type 2 diabetes, plus any updated R&D and share repurchase commentary at events such as the September 15, 2026 Morgan Stanley conference.
ASNDNOV.XETRA
Biotech & Genomic Medicine
Simply Wall St·3hRead more →
▲

BioMarin Reports Positive Phase 3 VOXZOGO Hypochondroplasia Data and Files sNDA

BioMarin Pharmaceutical reported positive Phase 3 CANOPY-HCH-3 results for VOXZOGO in children with hypochondroplasia and submitted a supplemental FDA application to expand the drug's use, while also adding Bristol Myers Squibb research leader Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee. The late-stage data cover an indication with no approved treatments, and the company said the combination of the results and the board appointment underscores its focus on deepening its rare disease franchise and scientific oversight. BioMarin's narrative projects $5.0 billion revenue and $1.3 billion earnings by 2029, requiring 14.0% yearly revenue growth and about a $1.2 billion earnings increase from $73.0 million today, with a $91.42 fair value cited, a 43% upside to its current price. More pessimistic analysts warn that heavy reliance on a few rare disease drugs and uncertainty around future indications could leave BioMarin short of pre-news expectations of about US$4.7 billion in revenue and roughly US$509.5 million in earnings by 2029.
BMRN ▲
Biotech & Genomic Medicine ▲
Simply Wall St·5hRead more →
▲

BioMarin Targets $200 Million Amicus Synergies as VOXZOGO Nears $1 Billion

BioMarin Pharmaceutical said it is progressing with the integration of Amicus Therapeutics and expects $200 million in annual non-GAAP cost savings, with most synergies realized in 2027 and full realization in 2028. Speaking at Morgan Stanley's Global Healthcare Conference, President and CEO Alexander Hardy said Amicus had about 505 employees and BioMarin expects to retain approximately 192 over the long term, with about 70% of the savings coming from general and administrative expenses and the remainder from duplicated research and development functions. Chief Financial Officer Brian Mueller said the deal should be accretive in its first year, with substantial accretion beginning next year, and that leverage is now expected to fall below 2.5 times by the middle of 2027, nearly a year earlier than the initial target. Hardy said VOXZOGO delivered 20% quarterly patient growth despite U.S. competition and is expected to reach $1 billion in revenue this year, which would make it BioMarin's first blockbuster product, while a potential FDA approval in hypochondroplasia is not incorporated into its 2026 outlook. BioMarin projects peak sales of approximately $1.4 billion for GALAFOLD and $1.2 billion for POMBILITI + OPFOLDA by the mid-2030s, and said PALYNZIQ grew 27% to $135 million while VIMIZIM has the potential to exceed $1 billion in revenue.
BMRN ▲
Biotech & Genomic Medicine ▲
MarketBeat·21hRead more →
© 2026 MarketDXNews